Premium
DEPTOR modulates activation responses in CD4 + T cells and enhances immunoregulation following transplantation
Author(s) -
Wedel Johannes,
Bruneau Sarah,
Liu Kaifeng,
Kong Sek Won,
Sage Peter T.,
Sabatini David M.,
Laplante Mathieu,
Briscoe David M.
Publication year - 2019
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.14995
Subject(s) - microbiology and biotechnology , foxp3 , cancer research , pi3k/akt/mtor pathway , effector , medicine , downregulation and upregulation , transplantation , biology , signal transduction , immunology , immune system , gene , biochemistry
DEPTOR is an evolutionarily conserved cell‐intrinsic binding partner of mTOR that functions as a negative regulator of signaling responses. In this study, we show that DEPTOR is expressed within CD4 + T cells, and we observed that its relative level of expression modulates differentiation as well as glucose utilization within CD4 + T effectors in vitro. Using knock‐in mice, we also find that induced expression of DEPTOR within CD4 + T regulatory cells stabilizes Foxp3 expression, shifts metabolism toward oxidative phosphorylation, and increases survival and suppressive function. In vivo, fully MHC mismatched cardiac allograft survival is significantly prolonged in knock‐in recipients and sustained recipient expression of DEPTOR in combination with costimulatory blockade induces long‐term graft survival. Furthermore, we show that the induced expression of DEPTOR in CD4 + T effectors fails to inhibit acute allograft rejection. Rather, prolonged survival is dominantly mediated via induced expression and function of DEPTOR within recipient CD4 + T regulatory cells. These collective findings identify DEPTOR as a novel protein that functions in CD4 + T cells to augment immunoregulation in vitro and in vivo.